UPS allocates $48 million to cold chain investments amid the rise in biologics.

      **TL;DR** UPS is committing $48 million to 27 temperature-controlled freight facilities across three continents in response to growing demand for biologics and GLP-1 drugs, with a goal of achieving $20 billion in healthcare revenue by the end of 2026.

      UPS has revealed an investment of $48 million to establish 27 temperature-controlled freight cross-dock facilities throughout the Americas, Europe, and Asia. These facilities will serve as short-term storage solutions for air and ground transport, maintaining specific temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen, as stated by the company.

      This investment is part of UPS's larger strategic shift towards creating a real-time digital replica of its entire logistics network, backed by substantial spending on acquisitions to position itself as the world's foremost provider of complex healthcare logistics. The company aims to achieve $20 billion in healthcare revenue by the close of 2026, which would account for approximately 18 percent of its total sales.

      **The importance of cold chain logistics today**

      The pharmaceutical sector is increasingly moving towards temperature-sensitive medications. Currently, about one-third of newly approved drugs are biologics, with over 85 percent of these requiring temperature-controlled management, according to PharmaSource.

      The market for temperature-sensitive biologics is anticipated to grow at an annual compound rate of 8.3 percent through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. This growth is largely driven by GLP-1 injectables like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, as well as cell and gene therapies and mRNA technologies.

      **Consequences of cold chain failures**

      The risks associated with cold chain failures are real and significant. Industry estimates suggest that global losses from temperature deviations could reach up to $35 billion each year, while the World Health Organization has estimated that inadequate temperature control can contribute to as much as 50 percent of worldwide vaccine waste.

      Kate Gutmann, executive vice president and president of international, healthcare, and supply chain solutions at UPS, stated, "We have aligned our investments with our healthcare customers’ specialized needs. We are helping patients access the medications and treatments they require."

      **Network growth through acquisitions**

      The expansion of cross-dock facilities builds on a series of acquisitions that have turned UPS Healthcare from a secondary operation into a primary growth driver. In 2025, UPS invested $1.6 billion in Canada's Andlauer Healthcare Group, enhancing its specialized cold chain transportation across North America.

      Prior acquisitions included Italy's Bomi Group, which brought temperature-controlled facilities to 14 countries and over 350 refrigerated vehicles, as well as European cold chain providers Frigo Trans and BPL. UPS also extended its Incheon air hub in South Korea, a market that imported nearly $9.7 billion in pharmaceutical products in 2025.

      **Aiming for $20 billion**

      UPS Healthcare now manages 19.2 million square feet of cGMP and GDP-compliant distribution space worldwide. The division generated its first $3 billion revenue quarter in the first quarter of 2026, positioning it to reach the $20 billion annual target set by CEO Carol Tomé when she prioritized healthcare as the company’s main strategic focus.

      The pharmaceutical industry’s pipeline indicates that demand for temperature-sensitive treatments will likely escalate. As AI-designed therapies and digitized patient pathways increase, the parcel companies that can guarantee a consistent temperature of 4 degrees Celsius from a factory in Basel to a clinic in Seoul will possess a logistical advantage that is hard to duplicate.